ABSTRACT
Clinical management of breast cancer (BC) metastasis remains an unmet need as it accounts for 90% of BC-associated mortality. Although the luminal subtype, which represents >70% of BC cases, is generally associated with a favorable outcome, it is susceptible to metastatic relapse as late as 15 years after treatment discontinuation. Seeking therapeutic approaches as well as screening tools to properly identify those patients with a higher risk of recurrence is therefore essential. Here, we report that the lipid-degrading enzyme fatty acid amide hydrolase (FAAH) is a predictor of long-term survival in patients with luminal BC, and that it blocks tumor progression and lung metastasis in cell and mouse models of BC. Together, our findings highlight the potential of FAAH as a biomarker with prognostic value in luminal BC and as a therapeutic target in metastatic disease.
Subject(s)
Amidohydrolases , Biomarkers, Tumor , Lung Neoplasms , Animals , Mice , Amidohydrolases/genetics , Lung Neoplasms/pathology , Neoplasm Recurrence, Local/pathologyABSTRACT
Presentamos el caso de una paciente con evisceración vaginal sin antecedentes de cirugía vaginal. La paciente fue intervenida en nuestro centro, realizándose una laparotomía con reposición de asas intestinales, corrección del defecto e histerectomía vaginal. En mujeres posmenopáusicas, la evisceración transvaginal se asocia a un aumento de la presión abdominal, la ulceración vaginal y los esfuerzos al defecar. En un 73% de los casos, existe algún tipo de cirugía vaginal previa. La clínica habitual es dolor, sangrado o sensación de masa en el introito. El íleo terminal es la víscera más frecuentemente implicada y el fórnix posterior de la vagina, el lugar más frecuente de herniación. La prevención está orientada a evitar intervenciones repetidas, alteraciones del suelo pélvico, hipoestrogenismo y aumento de la presión intraabdominal (AU)
We report the case of a patient with vaginal evisceration and no history of vaginal surgery. We performed a laparotomy with bowel replacement, correction of the defect and vaginal hysterectomy. In postmenopausal women, transvaginal evisceration is associated with increased abdominal pressure, vaginal ulceration and straining at stool. In 73% of patients, there is some type of prior vaginal surgery. The most common symptoms are pain, bleeding or sensation of a mass at the introitus. The most commonly involved viscera is the terminal ileum and the most common site of herniation is the posterior fornix of the vagina. Prevention is aimed at avoiding repeat interventions, pelvic floor disorders, hypoestrogenism, and increased abdominal pressure (AU)
